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Delta opioid agonists enhance antinociceptive eﬀects of mu-opioid agonists in many preclinical assays of acute nociception,
but delta/mu interactions in preclinical models of inflammation-associated pain have not been examined. This study examined
interactions between the delta agonist SNC80 [(+)-4-[(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-
N,N-diethylbenzamide] and the mu agonist analgesics methadone, morphine, and nalbuphine in an assay of capsaicin-induced
thermal allodynia in rhesus monkeys. Thermal allodynia was produced by topical application of capsaicin to the tail. Antiallodynic
eﬀects of methadone, morphine, and nalbuphine were evaluated alone or in combination with fixed proportions of SNC80
identical to proportions previously shown to enhance acute thermal antinociceptive eﬀects of these mu agonists in rhesus monkeys
(0.9 : 1 SNC80/methadone; 0.29 : 1 SNC80/morphine; 3.6 : 1 SNC80/nalbuphine). Methadone, morphine, and nalbuphine each
produced dose-dependent antiallodynia. SNC80 produced partial antiallodynia up to the highest dose tested (5.6mg/kg). SNC80
produced a modest, enantioselective, and naltrindole-reversible enhancement of methadone-induced antiallodynia. However,
SNC80 did not enhance morphine antiallodynia and only weakly enhanced nalbuphine antiallodynia. Overall, SNC80 produced
modest or no enhancement of the antiallodynic eﬀects of the three mu agonists evaluated. These results suggest that delta agonist-
induced enhancement of mu agonist antiallodynia may be weaker and less reliable than previously demonstrated enhancement of
mu agonist acute thermal nociception.
1. Introduction
Mu-opioid receptor agonists are eﬀective analgesics for the
treatment of many types of pain, but their clinical use is
limited by undesirable eﬀects that include sedation, respira-
tory depression, constipation, and high abuse liability [1, 2].
One strategy to improve the eﬀectiveness and/or safety of
mu agonist analgesics is to combine them with adjuncts
that target other pharmacological systems. For example, we
and others have reported that delta opioid receptor agonists
can selectively enhance the antinociceptive eﬀects of mu
agonists in assays of acute thermal pain while producing a
lesser enhancement, no enhancement, or an attenuation of
many undesirable eﬀects of mu agonists [3–7].Moreover, mu
agonists may produce a reciprocal attenuation in undesirable
eﬀects produced by some delta agonists (e.g., convulsant
activity [3]). These findings have been interpreted to suggest
that mixtures of delta and mu agonists, or single compounds
with mixed agonist activity at both delta and mu receptors,
may be useful as alternatives to selective mu agonists for the
treatment of pain.
The majority of studies on mu/delta antinociceptive
interactions have been conducted in assays that evaluate
behavioral responses to acute noxious stimuli, which are
defined as stimuli capable of producing tissue damage. How-
ever, responses to noxious stimuli are adaptive (e.g., by pro-
moting movement of an aﬀected limb away from a stimulus
that could cause tissue damage), and opioids are used clini-
cally to dampen these responses only as an adjunct to other
drugs in the context of general or epidural anesthesia [8–10].
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The far more common use of opioid analgesics is to treat
spontaneous or hypersensitive pain responses associated
with states such as inflammation, neuropathy, or cancer [1,
2]. For example, inflammation consequent to a burn, surgical
procedure, or other tissue damage is commonly associat-
ed with allodynia, which is defined as a pain-like response to
normally innocuous stimuli, and opioid analgesics reliably
attenuate inflammation-associated allodynia [11, 12]. Pre-
clinical procedures have been developed to examine eﬀects
of opioids and other drugs on inflammation-associated allo-
dynia [13], but interactions between delta andmu agonists in
these clinically relevant procedures have not been evaluated.
To address this knowledge gap, the present study eval-
uated interactions between the nonpeptidic delta agonist
SNC80 and the mu-opioid agonists methadone, morphine,
and nalbuphine in an assay of capsaicin-induced thermal
allodynia in rhesus monkeys. Capsaicin is an agonist at
TRPV1 receptors (Transient Receptor Potential cation chan-
nel, subfamily V, member 1), which are densely and sel-
ectively localized on the peripheral terminals of small unmy-
elinated C-fiber nociceptors [14]. Capsaicin-induced stim-
ulation of TRPV1 receptors increases excitability of these
nociceptors and produces an inflammation-like hypersensi-
tivity to thermal stimuli [15]. Either mu or delta agonists
administered alone have been shown previously to produce
antiallodynic eﬀects in this procedure [16, 17]. In this study,
SNC80 and each mu agonist were administered as fixed-pro-
portion mixtures that were shown previously to produce
synergistic eﬀects in an assay of acute thermal nociception in
rhesus monkeys [6]. We hypothesized that these same pro-
portions of SNC80 would enhance the antiallodynic eﬀects
of the mu agonists.
2. Materials and Methods
2.1. Subjects. Three male and one female adult rhesus mon-
keys (Macaca mulatta; Covance, Denver, PA) weighed be-
tween 7 and 10 kg during the course of these studies. All
monkeys had prior exposure to drugs (primarily dopaminer-
gic and opioid compounds) and to the behavioral procedures
in which they were tested. The subjects were individually
housed, and water was freely available. Their diet consisted
of Purina Lab Diet Fiber-PlusMonkey Biscuits no.5049 (PMI
Feeds, Inc., St. Louis, MO) supplemented with fresh fruit
twice weekly. A 12 h light/12 h dark cycle was in eﬀect (lights
on from 7AM–7 PM). Animal maintenance and research
were conducted in accordance with the guidelines provided
by the NIH Committee on Laboratory Animal Resources.
The facility was licensed by the United States Department of
Agriculture and accredited by the Association for the Asses-
sment and Accreditation of Laboratory Animal Care. Proto-
cols were approved by the Institutional Animal Care and Use
Committee. The health of the monkeys was monitored daily
by technical and veterinary staﬀ. Monkeys had visual, audi-
tory, and olfactory contact with other monkeys throughout
the study. Monkeys also had access to puzzle feeders, mirrors,
and chew toys to provide environmental enrichment. Music
was played daily in all housing rooms.
2.2. Assay of Capsaicin-Induced Thermal Allodynia. Monkeys
were seated in acrylic restraint chairs so that their tails
hung down freely. To determine tail-withdrawal latencies, the
lower 15 cm of each monkeys shaved tail was immersed into
a thermal container of warm water heated to the designated
temperature (see below for temperatures). The latency in
seconds for the monkey to remove its tail from the water was
measured using a handheld stopwatch. If the subject did not
withdraw its tail within 20 s, the tail was removed from the
water by the experimenter, and a latency of 20 s was assigned
to that measurement.
Experimental sessions were conducted once per week. At
the beginning of each session, tail withdrawal latencies were
determined for each monkey from water heated to 38, 42,
46, and 50◦C, and the order of temperature presentations
was randomized across sessions. By this procedure, baseline
temperature-eﬀect curves were determined in each monkey
at the beginning of each session, and the highest temperature
that failed to elicit tail withdrawal was determined (i.e., the
highest temperature to produce a tail withdrawal latency of
20 sec). Water heated to this “threshold” temperature then
served as the thermal stimulus for subsequent studies of allo-
dynia during that session. The threshold stimulus intensity
was 42◦C for two monkeys and 46◦C for the other two mon-
keys throughout the study.
Allodynia was elicited by topical application of capsaicin
as described previously [15, 18]. Following baseline tail with-
drawal latency determinations, a topical patch treated with
capsaicin solution or vehicle was prepared as described below
(see Section 2.4), and the patch was applied to a region
approximately 7 cm from the bottom of the tail for 5min.
After 5min, the patch was removed. Tail withdrawal latencies
were then redetermined 15, 30, 45, and 60min after patch
removal using the thermal stimulus identified from the
baseline temperature-eﬀect curve in each monkey (i.e., 42◦C
in two monkeys, 46◦C in the other two monkeys).
Three sets of pharmacological manipulations were
implemented. (1) First, eﬀects of mu and delta opioid ago-
nists administered alone were determined. Drugs and doses
studied were the high-eﬃcacy mu agonist methadone (0.32–
3.2mg/kg), the intermediate-eﬃcacy mu agonist morphine
(0.1–1.0mg/kg), the low-eﬃcacy mu agonist nalbuphine
(0.032–0.32mg/kg), the high-eﬃcacy delta agonist SNC80
(1.0–5.6mg/kg), and the inactive enantiomer of SNC80,
SNC67 (5.6mg/kg). (2) Second, eﬀects of delta/mu drug
mixtures were studied. The dose proportions of SNC80 in
combination with methadone (0.9 : 1 SNC80/methadone),
morphine (0.3 : 1 SNC80/morphine) and nalbuphine (3.6 : 1
SNC80/nalbuphine) were based on a previous study that
examined eﬀects of these mixtures in other behavioral proce-
dures in monkeys [6]. Specifically, these SNC80/mu agonist
proportions produced selective and synergistic enhancement
of the thermal antinociceptive eﬀects of methadone, mor-
phine, and nalbuphine. The proportion of SNC67 in com-
bination with methadone (0.9 : 1) was designed to match
the SNC80/methadone mixture with the highest proportion
of SNC80. (3) Third, antagonism studies were conducted
to evaluate the role of delta and mu receptors in medi-
ation of eﬀects produced by methadone alone and by
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the 0.9 : 1 SNC80/methadone mixture. Dose-eﬀect curves
for methadone and 0.9 : 1 SNC80/methadone were redeter-
mined after pretreatment with the delta-selective antagonist
naltrindole (1.0mg/kg) and the mu-selective opioid antago-
nist naltrexone (0.1mg/kg). In all studies, agonists and mix-
tures were administered 15min before application of the cap-
saicin patch, and antagonists were administered 30min
before the agonist or mixture. All studies with methadone
and morphine were conducted in one group of 3 monkeys.
All studies with nalbuphine were conducted in a diﬀerent
group of 3 monkeys. Two monkeys were used for all studies
with all drugs.
2.3. Data Analysis. Raw tail withdrawal latencies obtained
15, 30, 45, and 60min after removal of the capsaicin patch
were converted to PercentMaximumPossible Eﬀect (%MPE)
using the equation %MPE = [(Test Latency − Capsaicin
Alone Latency)/(20 − Capsaicin Alone Latency)] ∗ 100,
where “test latency” was the tail withdrawal latency obtained
at each time point after drug pretreatment + capsaicin patch
treatment, and “Capsaicin Alone Latency” was the latency
obtained at the corresponding time point after treatment
with the capsaicin patch alone. Data from all four time points
were then averaged to yield a mean %MPE for each monkey
during each session, and these mean%MPE values were then
used for graphs and statistical analysis.
ED50 values and 95% confidence limits were determined
by linear regression as the dose required to produce 50
%MPE (Prism 4.0c for Macintosh; GraphPad Software, San
Diego, CA). ED50s were considered to be significantly diﬀer-
ent if 95% confidence limits did not overlap. Data for SNC80/
mu agonist interactions were also analyzed by 2-way analysis
of variance (ANOVA), with mu agonist dose as one factor
and SNC80 proportion as the second factor. A significant
ANOVA was followed by the Holm-Sidak post hoc test. The
criterion for significance was P < 0.05.
2.4. Drugs. Methadone HCl, morphine sulfate, and naltrex-
one HCl were provided by the Drug Supply Program of the
National Institute on Drug Abuse (Bethesda, MD). SNC80,
SNC67, nalbuphine HCl, and naltrindole HCl were provided
by Kenner C. Rice (NIDA and NIAAA, Bethesda, MD).
Methadone, morphine, nalbuphine, naltrexone, and naltrin-
dole were dissolved in sterile water. SNC80 and SNC67 were
free bases dissolved in 2-3% lactic acid and sterile water to a
final concentration of 50mg/mL, and dilutions were made
with sterile water. All drugs were administered IM in the
thigh, and doses are expressed in the salt or base forms given
above.
Capsaicin (Sigma Chemical Co., St. Louis, MO) was dis-
solved in a vehicle composed of 70% alcohol and 30% sterile
water, and it was delivered transdermally (topical patch)
as described previously [15, 19]. Specifically, the patch was
composed of layers consisting of a 1 cm2 piece of tissue, 1-
cm2 piece of two-ply gauze, and a round adhesive band-
age aﬃxed to adhesive backing (23mm wide; Nexcare
Active, NM). The patch was then attached to a 12 cm long
elastic tape. The capsaicin solution (0.3mL) was slowly
dripped from a syringe onto the patch, and the concentration
Table 1: ED50 values (95% confidence limits) in mg/kg for the
antiallodynic eﬀects of methadone, morphine, and nalbuphine
administered alone or in combination with other drugs. Symbols
indicate significantly diﬀerent from mu agonist alone (∗) or from
0.9 : 1 SNC80/methadone alone (†) as indicated by nonoverlapping
confidence limits.
Treatment ED50 (95%CL)
Methadone
Methadone alone 0.98 (0.48–1.97)
0.9 : 1 SNC80/methadone 0.34 (0.21–0.56)
0.9 : 1 SNC67/methadone 1.03 (0.27–3.31)
Methadone + 0.1 NTX >10∗
Methadone + 1.0 NTI 1.37 (0.22–3.61)
0.9 : 1 SNC80 methadone + 0.1 NTX 2.97 (2.09–4.86)†
0.9 : 1 SNC80/methadone + 1.0 NTI 2.08 (0.98–5.52)†
Morphine
Morphine alone 0.41 (0.14–1.60)
0.29 : 1 SNC80/morphine 0.38 (0.22–0.68)
Nalbuphine
Nalbuphine alone 0.15 (0.07–0.43)
3.6 : 1 SNC80/nalbuphine 0.08 (0.04–0.17)
of capsaicin in the solution was individually determined for
each monkey as the lowest concentration to produce sus-
tained decreases in tail-withdrawal latencies from the thresh-
old temperature to ≤5 sec throughout the 1 hr testing period
[0.61mg/mL (2mM) in three monkeys and 2.44mg/ mL
(8mM) in the fourth monkey]. Within 30 s of preparing the
capsaicin patch, it was secured onto the monkey’s tail with
the elastic tape and left on for 5min.
3. Results
The mean baseline tail withdrawal latency (±SEM) from
water heated to the threshold temperature was 20.0 ± 0 sec
during the course of the study. Treatment with capsaicin
alone reduced tail withdrawal latencies to mean ± SEM
values of 2.2 ± 0.2 sec. The eﬀects of methadone, morphine
and nalbuphine alone are shown in Figures 1 and 2 (open
squares). All three mu agonists dose dependently blocked
capsaicin-induced thermal allodynia, and ED50 values for
each compound are shown in Table 1. SNC80 at doses up
to 3.2mg/kg failed to produce antiallodynia in any monkey
(maximal mean± SEM %MPE = −5.5± 3.6). A higher dose
of 5.6mg/kg SNC80 produced modest antiallodynic eﬀects
in two monkeys (%MPE of 56.5 and 37.5%), but this dose
produced a convulsion in a third monkey and was not tested
further. A dose of 5.6mg/kg SNC67 had no eﬀect in any
monkey (mean± SEM %MPE = 7.2± 3.1).
Figure 1(a) shows eﬀects of methadone in combination
with SNC80 and SNC67. There was a tendency for SNC80
to increase the potency of methadone as indicated by
a parallel left shift in the methadone dose-eﬀect curve.
The SNC80-induced reduction in the methadone ED50
was not statistically significant (Table 1). However, 2-way
ANOVA indicated significant main eﬀects of methadone
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Figure 1: Antiallodynic eﬀects produced by methadone administered alone or in combination with SNC80 or SNC67 (a), methadone after
pretreatment with 0.1mg/kg naltrexone or 1.0mg/kg naltrindole (b), and 0.9 : 1 SNC80/methadone after pretreatment with naltrexone or
naltrindole (c). Abscissae: dose methadone in mg/kg (log scale). Ordinates: percent maximum possible eﬀect (%MPE). All points show
mean± SEM for three monkeys. ED50 values are compared in Table 1. Data for methadone alone and 0.9 : 1 SNC80/methadone at doses of
0.32 and 1.0mg/kg methadone in the left panel were compared by 2-way ANOVA (see text for details). The asterisk in the left panel indicates
a significant diﬀerence from methadone alone.
dose [F(1, 2) = 27.4, P = 0.035] and SNC80 proportion
[F(1, 2) = 157.1, P = 0.006], but not a significant inter-
action [F(1, 2) = 2.1, P = 0.289]. The SNC80/methadone
mixture produced significantly greater antiallodynia than
methadone alone at a methadone dose of 0.32mg/kg (P <
0.05). SNC67, the inactive enantiomer of SNC80, had no
eﬀect on the methadone dose-eﬀect curve or ED50 value.
Figures 1(b) and 1(c) and Table 1 also show eﬀects of the
mu antagonist naltrexone and the delta antagonist naltrin-
dole on antiallodynia induced by methadone alone or the
0.9 : 1 SNC80/methadone mixture. Naltrexone significantly
increased ED50 values for both methadone and the SNC80/
methadone mixture, but naltrindole increased the ED50
value only for the mixture.
Figure 2 shows the eﬀects of morphine and nalbuphine
in combination with SNC80, and ED50 values are shown
in Table 1. These proportions of SNC80 failed to signifi-
cantly alter the ED50 values for either morphine or nal-
buphine. Two-way ANOVA also failed to show a significant
eﬀect of SNC80 on morphine-induced antiallodynia. How-
ever, 2-way ANOVA did reveal significant main eﬀects of
nalbuphine dose [F(2, 4) = 72.7, P < 0.001] and SNC80
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Figure 2: Antiallodynic eﬀects of morphine (a) or nalbuphine (b) administered alone or in a mixture with SNC80. Abscissae: dose morphine
or nalbuphine inmg/kg (log scale). Ordinates: percent maximumpossible eﬀect (%MPE). All points showmean±SEMdata from 3monkeys.
ED50 values are compared in Table 1, and data in each panel were analyzed by 2-way ANOVA (see text for details). The asterisk in the right
panel indicates a significant diﬀerence from nalbuphine alone.
proportion [F(1, 2) = 19.9, P = 0.047] as well as a signifi-
cant interaction [F(2, 4) = 8, 4, P = 0.037]. The 3.6 : 1
SNC80/nalbuphine mixture produced significantly greater
antiallodynia than nalbuphine alone at a dose of 0.1mg/kg
nalbuphine (P < 0.05).
4. Discussion
4.1. Eﬀects of Mu Agonists and SNC80 Alone. In agreement
with previous studies, the opioid analgesics methadone,
morphine, and nalbuphine each produced a dose-dependent
and complete blockade of capsaicin-induced thermal allo-
dynia in rhesus monkeys [16, 17, 20, 21]. The sensitivity
of methadone-induced antiallodynia to antagonism by the
mu-selective antagonist naltrexone but not the delta-selective
antagonist naltrindole suggests that methadone eﬀects in this
procedure were mediated by mu-opioid receptors. Similar
data suggest that the antiallodynic eﬀects of morphine are
also mu-receptor mediated in this procedure [16]. Receptor
mediation of the antiallodynic eﬀects of nalbuphine has
not been investigated, but many other eﬀects of nalbuphine
in rhesus monkeys are mu-receptor mediated [22, 23].
Methadone, morphine, and nalbuphine are distinguished in
part by their diﬀerent eﬃcacies at mu receptors, with meth-
adone having very high eﬃcacy, morphine intermediate
eﬃcacy, and nalbuphine relatively low eﬃcacy [24, 25]. The
finding that all three opioids fully blocked capsaicin-induc-
ed allodynia suggests that this procedure has relatively low
requirements for eﬃcacy at mu-opioid receptors. These data
are also consistent with the broad utility of mu agonist anal-
gesics for the treatment of inflammation-associated pain.
Eﬀects of SNC80 and SNC67 administered alone are also
consistent with previous studies [16, 26]. Thus, SNC80 at
doses up to 5.6mg/kg produced partial antiallodynia, where-
as the inactive enantiomer of SNC80, SNC67 was inactive.
The enantioselectivity and naltrindole reversibility [16] of
SNC80-induced antiallodynia are consistent with delta-
receptor mediation. In previous studies, a higher dose
of 10mg/kg SNC80 completely blocked capsaicin-induced
allodynia, and SNC80 also blocked or reversed thermal allo-
dynia produced by prostaglandin E2 and complete Freund’s
adjuvant [16]. In this study, doses above 5.6mg/kg SNC80
were not evaluated due to the emergence of convulsant eﬀects
in one monkey. These convulsant eﬀects have been described
previously, although they are usually produced only at doses
≥10mg/kg in rhesus monkeys [27, 28]. Overall, these results
suggest that delta agonists alone may have value for the
treatment of inflammation-associated pain, but the utility of
at least some of these compounds may be limited by the risk
of convulsant activity.
4.2. Eﬀects of SNC80 in Combination with Mu Agonists. Pre-
vious studies in rhesus monkeys found that SNC80 and other
high-eﬃcacy delta agonists enhanced the acute thermal anti-
nociceptive eﬀects of various mu agonists including meth-
adone, morphine, and nalbuphine [5, 6, 29, 30]. Numerous
studies have also been conducted to examine determinants
of delta/mu interactions in assays of acute nociception in
squirrel monkeys and rodents, and under many circum-
stances, delta agonists enhanced the antinociceptive eﬀects
of mu agonists [4, 7, 31, 32]. The present study extends these
evaluations of delta/mu interactions to an assay of inflam-
mation-like thermal allodynia in rhesus monkeys. As in the
assay of acute thermal nociception in rhesus monkeys [6],
SNC80 in a 0.9 : 1 SNC80/methadone mixture enhanced the
antiallodynic eﬀects ofmethadone. These eﬀects were enanti-
oselective and naltrindole reversible, suggesting that SNC80-
induced enhancement of methadone antiallodynia was
mediated by delta opioid receptors. However, by at least
two measures, SNC80-induced enhancement of mu agonist
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antiallodynia was weaker and less consistent than SNC80-
induced enhancement of mu agonist acute thermal antinoci-
ception. First, SNC80 produced a nonsignificant and less
than 3-fold decrease in the mean ED50 value for methadone-
induced antiallodynia. A significant eﬀect of SNC80 was
revealed only by two-way ANOVA at a single methadone
dose. In contrast, the same proportion of SNC80 produced a
significant andmore than a 5-fold decrease in the ED50 value
for methadone-induced acute thermal antinociception. Sec-
ond, proportions of SNC80 that significantly enhanced the
acute thermal antinociceptive eﬀects of the lower-eﬃcacy
mu agonists morphine and nalbuphine produced little or no
enhancement of the antiallodynic eﬀects of these compounds
in the present study.
There are several potential explanations for the relatively
modest delta/mu interactions observed in this study. For
example, it is well established that one critical determinant
of drug interactions is the proportion of drugs in a mixture
[33]. This study employed proportions of SNC80 that had
been shown previously to produce a robust and synergistic
enhancement of the acute thermal antinociceptive eﬀects of
methadone, morphine, and nalbuphine in rhesus monkeys
[6]. Although these proportions of SNC80 were less eﬀective
in enhancing antiallodynic eﬀects of these mu agonists, it is
possible that other delta agonist proportions might be more
eﬀective. At the very least, though, the present data sug-
gest a dissociation between optimal proportions of SNC80 to
enhance acute thermal antinociceptive versus antiallodynic
eﬀects of mu agonists. Another possibility is that mu agonist-
induced antinociception and antiallodynia may rely on
diﬀerent neural substrates with diﬀerent capabilities for sup-
porting synergistic delta/mu interactions. Thus, mu agonist-
induced acute thermal antinociception requires activity at
mu receptors located in the central nervous system, whereas
mu antiallodynia may also be mediated by peripheral mu
receptors located outside the central nervous system (e.g.,
on peripheral terminals of nociceptors) [17, 21]. In accord-
ance with eﬀects of SNC80/methadone mixtures in this
study, results with the mixed-action peptidic mu/delta
agonist MMP2200 [H(2)N-Tyr-D-Thr-Gly-Phe-Leu-Ser-
(O-beta-D-lactose)-CONH(2)] have provided evidence to
suggest that peripheral mu and delta receptors can interact
synergistically to mediate antiallodynia in rhesus monkeys
[18]. However, the degree of delta/mu synergy may be less
for peripheral versus central opioid receptor populations.
4.3. Clinical Implications. Insofar as this assay of capsaicin-
induced thermal allodynia models a clinically relevant
dimension of inflammatory pain, the present results suggest
that SNC80 and other delta agonists may have limited impact
on mu agonist analgesia in the context of inflammation.
However, even modest degrees of enhancement may be ben-
eficial if mixtures result in attenuated side eﬀects, and previ-
ous studies do suggest that mixtures of delta and mu agonists
may be less potent or less eﬀective than delta or mu agonists
alone in producing such undesirable eﬀects as suppression
of food-maintained operant responding, reinforcing eﬀects,
convulsions, or respiratory depression [3, 5, 6, 34]. More-
over, the present study modeled only one dimension
(thermal allodynia) of inflammatory pain. It is possible that
other dimensions of pain (e.g., mechanical allodynia or
spontaneous pain) may be more sensitive to delta/mu inter-
actions. For example, although this is the first study to assess
delta/mu interactions in an assay of inflammation-like ther-
mal hypersensitivity, synergistic delta/mu interactions have
been observed in mitigating mechanical antiallodynia caused
in rats by spinal nerve ligation [35] or intraplantar admin-
istration of nerve growth factor [36]. Overall, the range of
conditions under which delta/mu interactions may increase
the eﬀectiveness and/safety of mu agonist analgesics would
benefit from further study.
5. Conclusions
The main finding of this study was that the delta agonist
SNC80 produced only a modest enhancement of mu agonist-
induced antiallodynia in rhesus monkeys. These findings
contrast with the more consistent enhancement by SNC80
and other delta agonists of mu agonist-induced acute ther-
mal antinociception in rhesusmonkeys. These results suggest
that delta agonists may have only limited utility in enhancing
analgesic eﬀects of mu agonists in the clinically relevant con-
text of inflammatory pain.
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